Actinogen Medical Limited (ATGGF)

0.0150 0.0000 (0.00%) As of 09:40AM EDT. Market open.

Actinogen Medical Limited

109 Pitt Street
Suite 901 Level 9
Sydney, NSW 2000
Australia
61 2 8964 7401
https://www.actinogen.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.	MD, CEO & Director	331.25k	N/A	1960
Dr. Dana C. Hilt M.D.	Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board	248.16k	N/A	1953
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.	Head of Clinical Pharmacology & Lead Physician and Depression	60.93k	N/A	N/A
Mr. William Edward Souter BCom, IPAA, LLB (Adel)	Chief Financial Officer	N/A	N/A	N/A
Mr. Michael Roberts	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Fujun Li Ph.D.	Head of Manufacturing	N/A	N/A	N/A
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.	Company Secretary	N/A	N/A	1963

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Corporate governance

Actinogen Medical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.